Print

The IGBA

In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.

The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. The name of the organization was changed in September 2015 to the International Generic and Biosimilar Medicines Association (IGBA) to reflect the evolving nature of the industry.

Print

News

  • IGBA calls for full transparency and new timelines for impact assessment with regard to the voluntary WHO biological qualifier (BQ) proposal

    The International Generic and Biosimilar medicines Association (IGBA) welcomes the WHO’s continuous interest in the development of a global identification system for biological substances, as well as the decision to perform an impact study assessment of the voluntary Biological Qualifier Read More
  • IGBA Files Recommendations for USTR 2016 Special 301 Review

    February 5, 2016 – IGBA Files Recommendations for USTR 2016 Special 301 Review. Read More
  • Statement by the International Generic and Biosimilar Medicines Association on the Signing of the Trans-Pacific Partnership Agreement

    February 4, 2016 – Geneva, Switzerland – The International Generic and Biosimilar Medicines Association (IGBA) represents companies that are actively engaged in the global manufacturing and trading systems for medicines. We support enhanced cooperation between regulators to foster the global trade in Read More
  • IGBA letter to FDA regarding their biologics naming proposals

    The International Generic and Biosimilar Medicines Association (IGBA), representing member associations from the U.S. (GPhA), Canada (CGPA), Japan (JGA), Jordan (JAPM), Europe (EGA), South Africa (NAPM), and Taiwan (TGPA), as well as associate member associations from Australia (GBMA), Brazil (ProGenericos) Read More
  • IGBA Welcomes ICH Reform and Openness For New Members

    JOHANNESBURG, SOUTH AFRICA (November 3, 2015).- The International Generic and Biosimilar Medicines Association (IGBA) welcomed the International Conference on Harmonisation (ICH) reform and the opening of the process to new members, including international industry organisations. The IGBA fully recognises the Read More
  • 1
  • 2
  • 3
  • 4

Joint 22nd Medicines for Europe and 19th IGBA Annual Conference

18th Annual IGPA Conference

17th Annual IGPA Conference

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

Rue d'Arlon, 50
B-1000 Brussels, Belgium

Telephone: +32 (0)2 736 84 11
Fax: +32 (0)2 736 74 38
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.